These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 28359721

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bisphosphonates in the treatment of osteoporosis.
    Diab DL, Watts NB.
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [Abstract] [Full Text] [Related]

  • 4. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM, Cooper C, Kanis JA, Bruyère O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D, Ferrari S, IOF Epidemiology/Quality of Life Working Group.
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Osteonecrosis of the Jaw.
    Hamdy RC.
    J Clin Densitom; 2017 Sep; 20(1):1-2. PubMed ID: 28259260
    [No Abstract] [Full Text] [Related]

  • 7. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK.
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [Abstract] [Full Text] [Related]

  • 8. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
    McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.
    Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antiresorptives: Safety Concerns-Clinical Perspective.
    Brown JP.
    Toxicol Pathol; 2017 Oct; 45(7):859-863. PubMed ID: 29065818
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, International Task Force on Osteonecrosis of the Jaw.
    J Clin Densitom; 2017 Oct; 20(1):8-24. PubMed ID: 27956123
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
    Bagan J, Peydró A, Calvo J, Leopoldo M, Jiménez Y, Bagan L.
    Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
    [Abstract] [Full Text] [Related]

  • 17. Long-term use of bisphosphonates in osteoporosis.
    Watts NB, Diab DL.
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [Abstract] [Full Text] [Related]

  • 18. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.